1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Devices
NewCardio, Inc.

NewCardio, Inc.

NWCI
NewCardio, Inc.US flagOther OTC
0.00
USD
- -
- -
3,315.00Market Cap
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
TTM
Revenue per Share
0.1
- -
- -
- -
- -
0.01
0.01
Basic EPS, GAAP
- -
-0.09
-0.85
-0.71
-0.44
-0.4
-0.28
Free Cash Flow per Basic Share
- -
-0.01
-0.1
-0.23
-0.24
-0.16
-0.08
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
-0.29
-0.95
-1.02
-1.3
-1.48
-1.51
Tangible Book Value per Share
- -
-0.18
-0.68
0.15
-0.06
-0.11
-0.18
Basic Weighted Avg Shares
10
4
11
21
24
29
32
Sales/Revenue/Turnover
1
- -
- -
- -
- -
- -
- -
Operating Margin (%)
3.77
- -
- -
- -
- -
-3,674.93
-3,076.73
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
- -
- -
-9
-14
-10
-11
-9
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
3.77
- -
- -
- -
- -
-4,466.32
-3,705.12
Working Capital
- -
-1
-3
3
1
-1
-5
LT Debt
- -
- -
5
- -
- -
- -
- -
Total Equity
- -
-1
-7
3
-1
-3
-6
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'11
Jun'11
Sep'11
ST Debt
3
4
4
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
31
32
33
Market Capitalization
26
8
5

Working Capital

FRC

•

in mil. unless spec.
Mar'11
Jun'11
Sep'11
Total Current Assets
1
1
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
4
5
5
Payables & Accruals
1
1
2
ST Debt
3
4
4
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-1,872.53%
114.45%
Free Cash Flow
- -
351.85%
-19.76%
Net Income, GAAP
- -
262.33%
19.87%
Sales/Revenue/Turnover
- -
- -
-74.64%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
-0.1
-0.11
-0.14
- -
-0.44
2010
-0.16
-0.05
-0.08
- -
-0.4
2011
-0.08
-0.03
-0.07
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2009
- -
- -
- -
- -
- -
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Jess Emery Jones
Full Time Employees
10
Sector
Healthcare
Industry
Medical - Devices
Address
PO Box 658 Branchburg NJ United States of America 08853
IPO Date
Jan 4, 2008
Website
newcardio.com
Similar Companies
Intelligent Ultrasound Group plc (IUG.L)
Drägerwerk AG & Co. KGaA (DRW8.DE)
ShockWave Medical, Inc. (SWAV)
Outset Medical, Inc. (OM)
Xvivo Perfusion AB (publ) (0RKL.L)
IMRIS Inc. (IMRSQ)
Business
NewCardio, Inc. (NWCI) develops and commercializes proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease and cardiac safety assessment of drugs under development; its core products include QTinno, an automated cardiac safety solution employing algorithms to measure, analyze, and report on ECGs for Thorough QT and Phase I studies; CardioBip, a mobile ECG transtelephonic system with recording and transmitting device plus web-enabled software for remote patient monitoring; and my3KG, a software application assessing cardiac electrical activity in time and space via real-time 3-D analysis of standard 12-lead ECG electrodes. The company targets pharmaceutical, biotechnology, and academic organizations with preclinical cardiac safety services using human induced pluripotent stem cell-derived cardiomyocytes and high-throughput optical electrophysiology platforms to evaluate risks like QT prolongation and arrhythmias. Founded in 2004 and headquartered in Branchburg, New Jersey, NewCardio operates in the U.S. medical devices sector with approximately 10 employees under CEO Dr. Jess Jones; no major acquisitions, funding rounds, partnerships, or strategic shifts reported in the last 1-2 years.